SCHEMBL3976435

SCHEMBL3976435

CC(C)Oc1ccccc1-c1ccoc1C(=O)NN

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 2/20 0.42
SLC9A1 P19634 1/20 0.42
ALDH1A1 P00352 4/20 0.40
ACHE P22303 1/20 0.40
ALOX15 P16050 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CTSD P07339 1/20 0.39
KDM4E B2RXH2 2/20 0.39
LMNA P02545 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
GAA P10253 1/20 0.38
MAP2 P11137 1/20 0.36
RORC P51449 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
TP53 P04637 1/20 0.36
HPGD P15428 1/20 0.36
IDO1 P14902 1/20 0.36
TDO2 P48775 1/20 0.36
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3976785 0.81 GAA (0.43) ALDH1A1ALOX15HSD17B10CTSDKDM4E
SCHEMBL3976016 0.80 MEN1 (0.43) SLC9A1ALDH1A1ALOX15HSD17B10KDM4E
SCHEMBL3981591 0.78 SGMS2 (0.49) ALDH1A1KDM4ELMNAGAASMN1; SMN2
SCHEMBL3976647 0.77 IDO1 (0.34) IRAK4SLC9A1LMNASMN1; SMN2IDO1
SCHEMBL3977608 0.76 ALDH1A1 (0.47) ALDH1A1KDM4ESMN1; SMN2IDO1MEN1
SCHEMBL3977123 0.76 MAPT (0.39) ALDH1A1KDM4ETDP1GAASMN1; SMN2
SCHEMBL3977622 0.75 PTGER1 (0.37) ALDH1A1CTSDKDM4ELMNATDP1
SCHEMBL3982443 0.75 NPSR1 (0.43) ALDH1A1HSD17B10KDM4ELMNAGAA
SCHEMBL3976633 0.74 GCGR (0.41)
SCHEMBL3983270 0.73 FAAH (0.45) MEN1KMT2ABRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514452-B2 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD (JP) 2009-04-07 US disclosed
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-04 US disclosed
EP-1489077-A1 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same GLP1R, GCGR, GPR119 IRAK4 2927/4885SLC9A1 254/4885ALDH1A1 1389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.